Nerfasin

Main information

  • Trade name:
  • Nerfasin 2% 10% 20% solution for injection
  • Pharmaceutical form:
  • Solution for injection
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Nerfasin 2% 10% 20% solution for injection
    Ireland
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • Xylazine
  • Therapeutic area:
  • Cattle Food, Horses Food

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • NL/V/0157/002
  • Authorization date:
  • 22-02-2012
  • EU code:
  • NL/V/0157/002
  • Last update:
  • 09-08-2016

Patient Information leaflet: composition, indications, side effects, dosage, interactions, adverse reactions, pregnancy, lactation

A.LABELLING

PARTICULARSTOAPPEARONTHEOUTERPACKAGE

CARTONBOX

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Nerfasinvet.100 mg/ml,solutionforinjectionforcattleandhorses

Xylazine(ashydrochloride)

2. STATEMENTOFACTIVEANDOTHERSUBSTANCES

Perml:

Activesubstance:

Xylazine(ashydrochloride) 100.0 mg

(equivalentto 116.55 mgxylazinehydrochloride)

Excipients:

Methylparahydroxybenzoate(E218) 1.0 mg

3. PHARMACEUTICALFORM

Solutionforinjection.

4. PACKAGESIZE

Bottle

10 ml

25 ml

50 ml

5. TARGETSPECIES

Cattle(≥200 kg)andhorses.

6. INDICATION(S)

7. METHODANDROUTE(S)OFADMINISTRATION

Cattle:intramuscular.

Horses:intravenous.

Thestoppershouldnotbepuncturedmorethan20 times.

Numberofpunctures:.................

Readthepackageleafletbeforeuse.

8. WITHDRAWALPERIOD

Cattle:

Meatandoffal: 1 day

Milk: zerohours

Horses:

Meatandoffal: 1 day

Milk: zerohours

9. SPECIALWARNING(S),IFNECESSARY

Accidentalinjectionisdangerous–read thepackageleafletbeforeuse.

Accidentalintakeandcontactwithskin,eyesandmucousmembranesisdangerous–read the

packageleafletbeforeuse.

10.EXPIRYDATE

EXP:<month/year>

Shelflifeafterfirstopeningtheimmediatepackaging:28 days.

Oncebroached/opened,useby…..

11.SPECIALSTORAGECONDITIONS

Donotrefrigerateorfreeze.

12.SPECIFICPRECAUTIONSFORTHEDISPOSALOFUNUSEDPRODUCTSOR

WASTEMATERIALS,IFANY

Disposeofwastematerialinaccordancewithlocalrequirements.

13.THEWORDS“FORANIMALTREATMENTONLY”ANDCONDITIONSOR

RESTRICTIONSREGARDINGSUPPLYANDUSE,ifapplicable

Foranimaltreatmentonly.

Administrationonlybyaveterinarysurgeon.

14.THEWORDS“KEEPOUTOFTHEREACHANDSIGHTOFCHILDREN”

Keep outofthereachandsightofchildren.

15.NAMEANDADDRESSOFTHEMARKETINGAUTHORISATIONHOLDER

LeVetB.V.

Wilgenweg7

3421 TVOudewater

theNetherlands

16.MARKETINGAUTHORISATIONNUMBER(S)

<to becompletednationally>

17.MANUFACTURER’SBATCHNUMBER

Batch:<number>

MINIMUMPARTICULARSTOAPPEARONSMALLIMMEDIATEPACKAGING

UNITS

Bottle

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Nerfasinvet.100 mg/ml,solutionforinjectionforcattleandhorses

Xylazine(ashydrochloride)

2. QUANTITYOFTHEACTIVESUBSTANCE(S)

Containsperml:

Xylazine(ashydrochloride)100.0 mg

(equivalentto 116.55 mgxylazinehydrochloride)

3. CONTENTSBYWEIGHT,BYVOLUMEORBYNUMBEROFDOSES

10 ml

25 ml

50 ml

4. ROUTE(S)OFADMINISTRATION

Cattle:intramuscular.

Horses:intravenous.

5. WITHDRAWALPERIOD

Cattle:

Meatandoffal: 1 day

Milk: zerohours

Horses:

Meatandoffal: 1 day

Milk: zerohours

6. BATCHNUMBER

Batch:<number>

7. EXPIRYDATE

EXP:<month/year>

Shelflifeafterfirstopeningtheimmediatepackaging:28 days.

Oncebroached/opened,useby…

8. THEWORDS“FORANIMALTREATMENTONLY”

Foranimaltreatmentonly.

9. SPECIALWARNING(S),IFNECESSARY

Seepackageleafletforuserwarnings.

B. PACKAGELEAFLET

PACKAGELEAFLET

Nerfasinvet.100 mg/ml,solutionforinjectionforcattleandhorses

1. NAMEANDADDRESSOFTHEMARKETINGAUTHORISATIONHOLDER

ANDOFTHEMANUFACTURINGAUTHORISATIONHOLDERRESPONSIBLE

FORBATCHRELEASE, IFDIFFERENT

Marketingauthorisationholder

LeVetB.V.

Wilgenweg7

3421 TVOudewater

theNetherlands

Manufacturerforthebatchrelease:

ProdulabPharmaB.V.

Forellenweg16

4941 SJRaamsdonksveer

theNetherlands

2. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Nerfasinvet.100 mg/ml,solutionforinjectionforcattleandhorses

(AT,BE,CZ,DK, EL,FI,FR, HU,IS, LU,NL, NO,PL,SE,andSK)

Nerfasin100 mg/ml,solutionforinjectionforcattleandhorses

(ES,IE,IT,PTandUK)

Xylazine(ashydrochloride)

3. STATEMENTOFTHEACTIVESUBSTANCE(S)ANDOTHERINGREDIENTS

perml:

Activesubstance:

Xylazine(ashydrochloride): 100.0 mg

(equivalentto 116.55 mgxylazinehydrochloride)

Excipients:

Methylparahydroxybenzoate(E218)1.0 mg

Clear,colourlesssolution.

4. INDICATION(S)

Sedation.

Premedicationincombinationwithananaesthetic.

5. CONTRAINDICATIONS

Donotuseinanimalswithgastrointestinalobstructionasthemusclerelaxantproperties

ofthedrugappearto accentuatetheeffectsoftheobstructionandbecauseofpossible

vomiting.

Donotuseinanimalswithsevererenalorhepaticimpairment,respiratorydysfunction,

cardiacabnormalities,hypotensionand/orshock.

Donotuseindiabeticanimals.

Donotuseinanimalswithahistoryofseizures.

Donotuseincattleweighinglessthan200 kgbodyweight.Donotuseinfoalsyounger

than2 weeks.

Donotuseduringthelaststageofpregnancy(dangerofprematurebirth),exceptat

parturition(seesection12).

6. ADVERSEREACTIONS

Ingeneral,sideeffects,typicalforanα2-adrenergicagonist,likebradycardia,reversible

arrhythmiaandhypotensioncanoccur.Thermoregulationcanbeinfluencedand

consequentlybodytemperaturecandecreaseorincreasedependantontheambient

temperature.Depressionofrespirationand/orrespiratoryarrestcanoccur.

Cattle

Incattlexylazinemayinduceprematureparturition,anditalsoreducesimplantationof

theovum.

Cattle,whichhavereceivedhighdosesofxylazinesometimessufferfromloosefaeces

for24hoursafterwards.

Otheradversereactionsincludesnoring,profoundsalivation,ruminalatony,atonyofthe

tongue,regurgitation,bloating,nasalstridor,hypothermia,bradycardia,increased

urinationandreversibleprolapseofthepenis.

Horses

Horsesoftensweatastheeffectsofthesedationarewearingoff.

Severebradycardiaandreducedrespiratoryratehavebeenreportedespeciallyinhorses.

Followingadministrationtohorses,atransientrisefollowedbyafallinbloodpressure

usuallyoccurs.

Morefrequenturinationhasbeenreported

Muscletremorsandmovementinresponsetosharpauditoryorphysicalstimuliare

possible.Althoughrare,violentreactionshavebeenreportedinhorsesfollowingthe

administrationofxylazine.

Ataxiaandreversibleprolapseofthepenismayoccur.

Inveryrarecasesxylazinemayinducemildcolicasthegutmotilityisdepressed

temporarily.Asapreventivemeasurethehorseshouldreceivenofeedaftersedation

untiltheeffecthasfadedcompletely.

Ifyounoticeanyseriouseffectsorothereffectsnotmentionedinthisleaflet,pleaseinform

yourveterinarysurgeon.

7. TARGETSPECIES

Cattle(≥200 kg)andhorses.

8. DOSAGEFOREACHSPECIES,ROUTE(S)ANDMETHODOF

ADMINISTRATION

Cattle:intramuscular.

Horses:intravenous.

*Cattle:

Dosage:

Dosageforcattle

Dosagelevel§ xylazine

(mg/kg) Nerfasin100 mg/ml

(ml/100kg) Nerfasin100mg/ml

(ml/500kg)

I 0.05 0.05 0.25

II 0.1 0.1 0.5

III 0.2 0.2 1

IV 0.3 0.3 1.5

§§Dose1:Sedation,withaslightdecreaseofmuscletone.Theabilityto standis

maintained.

Dose2:Sedation,markeddecreaseofmuscletoneandsomeanalgesia.Theanimalusually

remainsstanding,butmayliedown.

Dose3:Deepsedation,furtherdecreaseofmuscletoneandadegreeofanalgesia.The

animalliesdown.

Dose4:Verydeepsedation,aprofounddecreaseinmuscletoneandadegreeofanalgesia.

Theanimalliesdown.

*Horses

Dosage:singledoseof0.6-1 mgxylazineperkgbodyweight.

(0.6-1 mlproductper100 kgbodyweight).

Thestoppershouldnotbepuncturedmorethan20 times.

9. ADVICEONCORRECTADMINISTRATION

Theintravenousinjectionto horsesshouldbegivenslowly.

Thenumberofpuncturesshouldberecordedontheouterpackaging

10.WITHDRAWALPERIOD

Cattle:

Meatandoffal: 1 day

Milk: zerohours

Horses:

Meatandoffal: 1 day

Milk: zerohours

11.SPECIALSTORAGEPRECAUTIONS

Keep outofthereachandsightofchildren.

Donotrefrigerateorfreeze.

DonotuseaftertheexpirydatestatedonthevialandthecartonafterEXP.

Shelf-lifeafterfirstopeningtheimmediatepackaging:28days.

12.SPECIALWARNING(S)

Specialwarningsforeachtargetspecies

Horses:

Xylazineinhibitsthenormalintestinalmotility.Therefore,itshouldonlybeusedin

horseswithcolic,thatarenotresponsiveto analgesics.Theuseofxylazineshouldbe

avoidedinhorseswithcaecalmalfunction.

Aftertreatmentofhorseswithxylazine,theanimalsarereluctantto walk,so whenever

possiblethedrugshouldbeadministeredintheplacewherethetreatment/investigation

isgoingtotakeplace.

Cautionshouldbetakenintheadministrationoftheproducttohorsessusceptibleto

laminitis.

Horseswithairwaydiseaseormalfunctionmaydeveloplife-threateningdyspnoea.

Thedoseshouldbekeptaslowaspossible.

Theassociationwithotherpre-anaestheticagentsoranaestheticagentsshouldbethesubjectofa

benefit/riskassessment.Thisassessmentshouldconsiderthecompositionoftheproducts,their

doseandthenatureofthesurgery.Recommendeddosagesarelikelytovaryaccordingtothe

choiceoftheanaestheticassociation.

Cattle:

Ruminantsarehighlysusceptibleto theeffectsofxylazine.Normallycattleremain

standingatthelowerdoses, butsomeanimalsmayliedown.Atthehighest

recommendeddosesmostanimalswillliedownandsomeanimalsmaylapseinlateral

recumbency.

Reticulo-ruminalmotorfunctionsaredepressedafterinjectionofxylazine.Thismay

resultsinbloat.Itisadvisabletowithholdfeedandwaterforseveralhoursbefore

administrationofxylazine.

Incattletheabilitytoeructate,coughandswallowisretainedbutreducedduringthe

periodofsedation,thereforecattlemustbecloselywatchedduringtherecoveryperiod:

theanimalsshouldbemaintainedinsternalrecumbency.

Incattlelifethreateningeffectsmayoccurafterintramusculardosesabove0.5 mg/kg

bodyweight(respiratoryandcirculatoryfailure).Thereforeveryprecisedosingis

required.

Thisproductshouldonlybeusedincattleweighing200 kgormore.Sinceitishighly

concentrated,aslightdeviationfromtheactualvolumeto beinjectedmaycauseserious

adversereactions.Incasecattleweighinglessthan200 kgneedto betreated,xylazine

withalowerstrengthshouldbeused(e.g.20 mg/ml).

Theassociationwithotherpre-anaestheticagentsoranaestheticagentsshouldbethesubjectofa

benefit/riskassessment.Thisassessmentshouldconsiderthecompositionoftheproducts,their

doseandthenatureofthesurgery.Recommendeddosagesarelikelytovaryaccordingtothe

choiceoftheanaestheticassociation.

Specialprecautionsforuseinanimals

Keep theanimalscalm,becausetheymayrespondto externalstimuli.

Avoidintra-arterialadministration.

Tympanymayoccasionallyoccurinrecumbentcattleandcanbeavoidedbymaintaining

theanimalinsternalrecumbency.

Toavoidaspirationofsalivaorfood,lowertheanimal’sheadandneck.Fasttheanimals

beforeuseoftheproduct.

Olderandexhaustedanimalsaremoresensitiveto xylazine,whilstnervousorhighly

excitableanimalsmayrequirearelativelyhighdose.

Incaseofdehydration,xylazineshouldbeusedcautiously.

Donotexceedtherecommendeddosage.

Followingadministrationanimalsshouldbeallowedto restquietlyuntilthefulleffect

hasbeenreached.

Itisadvisedtocoolanimalswhentheambienttemperatureisabove25°Candto keep

animalswarmatlowtemperatures.

Forpainfulprocedures,xylazineshouldalwaysbeusedincombinationwithlocalor

generalanaesthesia.

Xylazineproducesacertaindegreeofataxia;therefore,xylazinemustbeusedcautiously

inproceduresinvolvingthedistalextremitiesandinstandingcastrationsinthehorse.

Treatedanimalsshouldbemonitoreduntiltheeffecthasfadedtotally(e.g.cardiacand

respiratoryfunction,alsointhepost-operativephase)andshouldbesegregatedtoavoid

bullying.

Specialprecautionsto betakenby thepersonadministeringtheveterinarymedicinal

producttoanimals

Incaseofaccidentaloralintakeorself-injection,seek medicaladviceimmediatelyand

showthepackageleafletto thephysicianbutDONOTDRIVEassedationandchanges

inbloodpressuremayoccur.

Avoidskin,eyeormucosalcontact.

Washtheexposedskinimmediatelyafterexposurewithlargeamountsofwater.

Removecontaminatedclothesthatareindirectcontactwithskin.

Inthecaseofaccidentalcontactoftheproductwitheyes,rinseabundantlywithfresh

water.Ifsymptomsoccur,seek theadviceofaphysician.

Ifpregnantwomenhandletheproduct,specialcautionshouldbeobservednotto self-

injectasuterinecontractionsanddecreasedfoetalbloodpressuremayoccurafter

accidentalsystemicexposure.

Advicetodoctors:

Xylazineisanα2-adrenoreceptoragonist,symptomsafterabsorptionmayinvolveclinical

effectsincludingdose-dependentsedation,respiratorydepression,bradycardia,

hypotension,adrymouthandhyperglycaemia.Ventriculararrhythmiashavealsobeen

reported.Respiratoryandhaemodynamicsymptomsshouldbetreatedsymptomatically.

Useduringpregnancy,lactationorlay

Althoughlaboratorystudiesinratshavenotshownanyevidenceofteratogenicor

foetotoxiceffectstheuseoftheproductduringthefirsttwotrimestersofpregnancyshould

onlybemadeaccordingtothebenefit/riskassessmentbytheresponsibleveterinarian.

Donotuseinthelaterstagesofpregnancy(particularlyincattle)exceptatparturition,

becausexylazinecausesuterinecontractionsanditmayinduceprematurelabour.

Donotuseincattlereceivingovumtransplantsastheincreaseduterinetonemayreduce

thechanceofimplantationoftheovum.

Interactionwithothermedicinalproductsandotherformsofinteraction

OtherCNSdepressantagents(barbiturates,narcotics,anaesthetics,tranquillizers,etc.)may

causeadditiveCNSdepressionifusedwithxylazine.Dosagesoftheseagentsmayneedto

bereduced.Xylazineshouldthereforebeusedcautiouslyincombinationwithneuroleptics

ortranquillizers.

Xylazineshouldnotbeusedincombinationwithsympathomimeticdrugssuchas

epinephrineasventriculararrhythmiamayfollow.

Theconcurrentintravenoususeofpotentiatedsulphonamideswithalpha-2agonistshas

beenreportedtocausecardiacarrhythmiaswhichmaybefatal.Whilstnosucheffectshave

beenreportedwiththisproduct,itisrecommendedthatintravenousadministrationof

Trimethoprim/Sulphonamidecontainingproductsshouldnotbeundertakenwhenhorses

havebeensedatedwithxylazine.

Overdose(symptoms,emergency procedures,antidotes),ifnecessary

Intheeventofanaccidentaloverdose,cardiacarrhythmias,hypotension,andprofound

CNSandrespiratorydepressionmayoccur.Seizureshavealsobeenreportedafteran

overdose.Xylazinecanbeantagonizedbyα2-adrenergicantagonists.

Thefollowingantidotesarerecommendedinoverdose:

TargetspeciesActivesubstance Dosage

Cattle Atipamezole

Yohimbine

4-Aminopyridine 0.03 mg/kg

0.125 mg/kg

0.3 mg/kg

Horses Atipamezol 0.15 mg/kg

Totreattherespiratorydepressanteffectsofxylazine,mechanicallyrespiratorysupport

withorwithoutrespiratorystimulants(e.g.doxapram)canberecommended.

13.SPECIALPRECAUTIONSFORTHEDISPOSALOFUNUSEDPRODUCTOR

WASTEMATERIALS,IFANY

Medicinesshouldnotbedisposedofviawastewaterorhouseholdwaste.

Askyourveterinarysurgeonhowtodisposeofmedicinesnolongerrequired.These

measuresshouldhelpto protecttheenvironment.

14.DATEONWHICHTHEPACKAGELEAFLETWASLASTAPPROVED

<DDmonthYYYY>

15.OTHERINFORMATION

Bottlescontaining10ml,25 mlor50 ml.

Notallpack sizesmaybemarketed.

Administrationonlybyaveterinarysurgeon.

MAnumber:

<to beestablishednationally.

13-9-2018

BioLyte Laboratories Issues Voluntary Nationwide Recall Due to the Voluntary Nationwide Recall initiated by King Bio Inc. (a Raw Material Supplier) for NeoRelief for Muscle Cramping and Restlessness Topical Gel Due to Possible Microbial Contamination

BioLyte Laboratories Issues Voluntary Nationwide Recall Due to the Voluntary Nationwide Recall initiated by King Bio Inc. (a Raw Material Supplier) for NeoRelief for Muscle Cramping and Restlessness Topical Gel Due to Possible Microbial Contamination

BioLyte Laboratories is voluntarily recalling lot numbers 1138, 1139, 1146, and 1160 of NeoRelief for Muscle Cramping and Restlessness Topical Gel to the retail and consumer level. King Bio Inc., a manufacturer of some of the active ingredients in this product, has been found to have some water contamination issues that potentially could have affected this product. King Bio has issued a recall of these active ingredients in BioLyte’s lot specific product. To date, there have been no reports of illness or...

FDA - U.S. Food and Drug Administration

28-6-2018

Minister Bruno Bruins verbetert transparantie zorgverzekeringen

Minister Bruno Bruins verbetert transparantie zorgverzekeringen

Er zijn in Nederland 55 verschillende standaard basisverzekeringen. In de praktijk worden verzekeringen onder allerlei namen en in verschillende verpakkingen aangeboden. Een van de verpakkingsvormen zijn de ongeveer 51.000 verschillende collectieve zorgverzekeringen. Hierdoor is de zorgverzekeringsmarkt ondoorzichtig geworden en is goed vergelijken een haast onmogelijke opgave. Minister Bruno Bruins (Medische Zorg) wil daarom dat zorgverzekeraars zorgen voor meer transparantie, onder andere door precies ...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

8-6-2018

Orphan designation:  Mepolizumab,  for the: Treatment of Churg-Strauss syndrome

Orphan designation: Mepolizumab, for the: Treatment of Churg-Strauss syndrome

On 12 March 2013, orphan designation (EU/3/13/1116) was granted by the European Commission to Glaxo Group Ltd, United Kingdom, for mepolizumab for the treatment of Churg-Strauss syndrome.

Europe - EMA - European Medicines Agency

4-6-2018

Hospira Issues a Voluntary Nationwide Recall for Two Lots of Naloxone Hydrochloride Injection, USP, in the Carpuject™ Syringe System due to the Potential Presence of Particulate Matter

Hospira Issues a Voluntary Nationwide Recall for Two Lots of Naloxone Hydrochloride Injection, USP, in the Carpuject™ Syringe System due to the Potential Presence of Particulate Matter

Hospira, Inc., a Pfizer company, is voluntarily recalling lots 72680LL and 76510LL of Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL, Carpuject Single-use cartridge syringe system (NDC 0409-1782-69), to the hospital/institution level due to the potential presence of embedded and loose particulate matter on the syringe plunger.

FDA - U.S. Food and Drug Administration

4-6-2018

Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL in the Carpuject™ Single-use Cartridge Syringe System   by Hospira: Recall - Due to the Potential Presence of Particulate Matter

Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL in the Carpuject™ Single-use Cartridge Syringe System by Hospira: Recall - Due to the Potential Presence of Particulate Matter

The patient has a low likelihood of experiencing adverse events ranging from local irritation, allergic reactions, phlebitis, end-organ granuloma, tissue ischemia, pulmonary emboli, pulmonary dysfunction, pulmonary infarction, and toxicity.

FDA - U.S. Food and Drug Administration

28-11-2018

Econor (Elanco GmbH)

Econor (Elanco GmbH)

Econor (Active substance: Valnemulin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)8038 of Wed, 28 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/42/T/54

Europe -DG Health and Food Safety

26-11-2018

Wakix (Bioprojet Pharma)

Wakix (Bioprojet Pharma)

Wakix (Active substance: Pitolisant hydrochloride) - Centralised - Yearly update - Commission Decision (2018)7974 of Mon, 26 Nov 2018

Europe -DG Health and Food Safety

21-11-2018

EU/3/18/2097 (Bayer AG)

EU/3/18/2097 (Bayer AG)

EU/3/18/2097 (Active substance: Larotrectinib) - Orphan designation - Commission Decision (2018)7807 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/116/18

Europe -DG Health and Food Safety

21-11-2018

EU/3/18/2082 (Takeda Pharma A/S)

EU/3/18/2082 (Takeda Pharma A/S)

EU/3/18/2082 (Active substance: 5-{(1R,2R)-2-[(cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride) - Orphan designation - Commission Decision (2018)7791 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/040/18

Europe -DG Health and Food Safety

13-11-2018

EU/3/17/1836 (Zogenix GmbH)

EU/3/17/1836 (Zogenix GmbH)

EU/3/17/1836 (Active substance: Fenfluramine hydrochloride) - Transfer of orphan designation - Commission Decision (2018)7576 of Tue, 13 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/233/16/T/01

Europe -DG Health and Food Safety

13-11-2018

EU/3/13/1219 (Zogenix GmbH)

EU/3/13/1219 (Zogenix GmbH)

EU/3/13/1219 (Active substance: Fenfluramine hydrochloride) - Transfer of orphan designation - Commission Decision (2018)7575 of Tue, 13 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/140/13/T/01

Europe -DG Health and Food Safety

1-11-2018

Dexdomitor (Orion Corporation)

Dexdomitor (Orion Corporation)

Dexdomitor (Active substance: dexmedetomidine hydrochloride) - Centralised - Yearly update - Commission Decision (2018)7380 of Thu, 01 Nov 2018

Europe -DG Health and Food Safety

31-10-2018

Evista (Daiichi Sankyo Europe GmbH)

Evista (Daiichi Sankyo Europe GmbH)

Evista (Active substance: Raloxifene hydrochloride) - Centralised - Yearly update - Commission Decision (2018)7342 of Wed, 31 Oct 2018

Europe -DG Health and Food Safety

2-10-2018

IntronA (Merck Sharp and Dohme B.V.)

IntronA (Merck Sharp and Dohme B.V.)

IntronA (Active substance: Interferon alfa-2b) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6487 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/281/T/116

Europe -DG Health and Food Safety

26-9-2018

Sileo (Orion Corporation)

Sileo (Orion Corporation)

Sileo (Active substance: Dexmedetomidine hydrochloride) - Centralised - Yearly update - Commission Decision (2018)6325 of Wed, 26 Sep 2018

Europe -DG Health and Food Safety

10-8-2018

Brinavess (Correvio)

Brinavess (Correvio)

Brinavess (Active substance: vernakalant hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5523 of Fri, 10 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1215/T/31

Europe -DG Health and Food Safety

30-7-2018

Segluromet (Merck Sharp and Dohme B.V.)

Segluromet (Merck Sharp and Dohme B.V.)

Segluromet (Active substance: ertugliflozin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5103 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4314/T/2

Europe -DG Health and Food Safety

30-7-2018

Ceplene (Noventia Pharma Srl)

Ceplene (Noventia Pharma Srl)

Ceplene (Active substance: Histamine dihydrochloride) - Centralised - Renewal - Commission Decision (2018)5116 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/796/R/36

Europe -DG Health and Food Safety

23-7-2018

Optruma (Eli Lilly Nederland B.V.)

Optruma (Eli Lilly Nederland B.V.)

Optruma (Active substance: Raloxifene hydrochloride) - Centralised - Yearly update - Commission Decision (2018)4893 of Mon, 23 Jul 2018

Europe -DG Health and Food Safety

23-7-2018

PecFent (Kyowa Kirin Holdings B.V.)

PecFent (Kyowa Kirin Holdings B.V.)

PecFent (Active substance: Fentanyl ) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4890 of Mon, 23 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1164/T/46

Europe -DG Health and Food Safety

12-7-2018

Econor (Elanco Europe Ltd)

Econor (Elanco Europe Ltd)

Econor (Active substance: Valnemulin hydrochloride) - Centralised - Yearly update - Commission Decision (2018)4580 of Thu, 12 Jul 2018

Europe -DG Health and Food Safety

11-7-2018

Ariclaim (Eli Lilly Nederland B.V.)

Ariclaim (Eli Lilly Nederland B.V.)

Ariclaim (Active substance: duloxetine hydrochloride) - Centralised - Withdrawal - Commission Decision (2018)4515 of Wed, 11 Jul 2018

Europe -DG Health and Food Safety

5-7-2018

Scientific guideline:  Draft pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance, draft: consultation open

Scientific guideline: Draft pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance, draft: consultation open

This document provides product-specific guidance on the demonstration of the bioequivalence of pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml.

Europe - EMA - European Medicines Agency

3-7-2018

Efficib (Merck Sharp and Dohme B.V.)

Efficib (Merck Sharp and Dohme B.V.)

Efficib (Active substance: sitagliptin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4254 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/896/T/90

Europe -DG Health and Food Safety

3-7-2018

Ristfor (Merck Sharp and Dohme B.V.)

Ristfor (Merck Sharp and Dohme B.V.)

Ristfor (Active substance: sitagliptin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4249 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1235/T/77

Europe -DG Health and Food Safety

3-7-2018

Velmetia (Merck Sharp and Dohme B.V.)

Velmetia (Merck Sharp and Dohme B.V.)

Velmetia (Active substance: sitagliptin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4252 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/862/T/93

Europe -DG Health and Food Safety

3-7-2018

Janumet (Merck Sharp and Dohme B.V.)

Janumet (Merck Sharp and Dohme B.V.)

Janumet (Active substance: sitagliptin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4251 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/861/T/90

Europe -DG Health and Food Safety

29-6-2018

EU/3/18/2028 (BioCryst UK Ltd)

EU/3/18/2028 (BioCryst UK Ltd)

EU/3/18/2028 (Active substance: (R)-1-(3-(aminomethyl) phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochloride) - Orphan designation - Commission Decision (2018)4173 of Fri, 29 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/003/18

Europe -DG Health and Food Safety

27-6-2018

Dafiro HCT (Novartis Europharm Limited)

Dafiro HCT (Novartis Europharm Limited)

Dafiro HCT (Active substance: amlodipine besylate / valsartan / hydrochlorothiazide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4084 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1160/T/68

Europe -DG Health and Food Safety

14-6-2018

Kuvan (BioMarin International Limited)

Kuvan (BioMarin International Limited)

Kuvan (Active substance: sapropterin dihydrochloride) - Centralised - Yearly update - Commission Decision (2018)3859 of Thu, 14 Jun 2018

Europe -DG Health and Food Safety

12-6-2018

EU/3/10/811 (Celgene Europe B.V.)

EU/3/10/811 (Celgene Europe B.V.)

EU/3/10/811 (Active substance: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate) - Transfer of orphan designation - Commission Decision (2018)3809 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/092/10/T/03

Europe -DG Health and Food Safety

12-6-2018

EU/3/10/810 (Celgene Europe B.V.)

EU/3/10/810 (Celgene Europe B.V.)

EU/3/10/810 (Active substance: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate) - Transfer of orphan designation - Commission Decision (2018)3808 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/084/10/T/03

Europe -DG Health and Food Safety

12-6-2018

EU/3/10/794 (Celgene Europe B.V.)

EU/3/10/794 (Celgene Europe B.V.)

EU/3/10/794 (Active substance: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate) - Transfer of orphan designation - Commission Decision (2018)3803 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/069/10/T/03

Europe -DG Health and Food Safety

12-6-2018

EU/3/11/888 (Gilead Sciences Ireland UC)

EU/3/11/888 (Gilead Sciences Ireland UC)

EU/3/11/888 (Active substance: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt) - Transfer of orphan designation - Commission Decision (2018)3802 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/152/10/T/03

Europe -DG Health and Food Safety

12-6-2018

EU/3/11/887 (Gilead Sciences Ireland UC)

EU/3/11/887 (Gilead Sciences Ireland UC)

EU/3/11/887 (Active substance: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt) - Transfer of orphan designation - Commission Decision (2018)3801 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/020/11/T/03

Europe -DG Health and Food Safety

12-6-2018

EU/3/11/886 (Gilead Sciences Ireland UC)

EU/3/11/886 (Gilead Sciences Ireland UC)

EU/3/11/886 (Active substance: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt) - Transfer of orphan designation - Commission Decision (2018)3799 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/019/11/T/03

Europe -DG Health and Food Safety

4-6-2018

Yervoy (Bristol-Myers Squibb Pharma EEIG)

Yervoy (Bristol-Myers Squibb Pharma EEIG)

Yervoy (Active substance: ipilimumab) - Centralised - 2-Monthly update - Commission Decision (2018)3618 of Mon, 04 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2213/II/55

Europe -DG Health and Food Safety

30-5-2018

Eviplera (Gilead Sciences Ireland UC)

Eviplera (Gilead Sciences Ireland UC)

Eviplera (Active substance: emtricitabine / rilpivirine (as hydrochloride) / tenofovir disoproxil (as fumarate)) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3453 of Wed, 30 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2312/T/91

Europe -DG Health and Food Safety